Chimeric antigen receptor (CAR) T-cell therapy is a cell-based treatment for hematological malignancies, offering potential for clinical remission of refractory disease. Nonetheless, immune-mediated neurotoxicity can occur post-treatment and we present a unique case of a pharyngo-brachial cervical variant of GBS (Guillain-Barre Syndrome) post-CAR T-cell therapy.
No takes yet. Share an insight, caveat, or question.
Raju et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: